Summary: Background: Tryptase, a major secretory product of human mast cells has been implicated as a key mediator of allergic inflammation. Genetic variation in the tryptases is extensive, and α‐tryptase, an allelic variant of the more extensively studied β‐tryptase, is absent in substantial numbers of the general population. The degree to which α‐tryptase expression may be associated with asthma has not been studied. We have investigated the α‐tryptase gene copy number variation and its potential associations with phenotypes of asthma.Objectives: Caucasian families (n = 341) with at least two asthmatic siblings (n = 1350) were genotyped for the α‐tryptase alleles, using high‐resolution melting assays. Standards for the possible α‐/β‐tryptase ratios were constructed by cloning α‐and β‐tryptasePCRproducts to generate artificial templates. Association analysis of asthma affection status and related phenotypes [total and allergen‐specific serumIgE, bronchial hyperresponsiveness to methacholine, forced expiratory volume in 1s (FEV1) and atopy and asthma severity scores] was undertaken using family‐based association tests (FBAT).Results: Four consistent melting patterns for the α‐tryptase genotype were identified with alleles carrying null, one or two copies of the α‐tryptase allele. Possessing one copy of α‐tryptase was significantly associated with lower serum levels of total and dust mite‐specificIgElevels and higherFEV1measurements, while two copies were related to higher serum concentrations of total and dust mite‐specificIgEand greater atopy severity scores.Conclusions and Clinical Relevance: Associations of α‐tryptase copy number with serumIgElevels, atopy scores and bronchial function may reflect roles for tryptases in regulatingIgEproduction and other processes in asthma.
31 January 2018 in Clinical & Experimental Allergy
Summary: Background: Tryptase, the most abundant protease of the human mast cell, has been implicated as a key mediator of allergic inflammation that acts through activation ofPAR2.Objectives: To investigate the contribution ofPAR2 in the pro‐inflammatory actions mediated by tryptase in a mice model.Methods: We have injected recombinant human βII‐tryptase into the peritoneum ofPAR2‐deficient and wild‐type C57BL/6 mice. After 6, 12 and 24 hours, mice were killed, peritoneal lavage performed and inflammatory changes investigated.Results: Tryptase stimulated an increase in neutrophil numbers in the peritoneum, but responses did not differ betweenPAR2‐deficient and wild‐type mice. Heat inactivation of tryptase or pre‐incubation with a selective tryptase inhibitor reduced neutrophilia, but neutrophil accumulation was not elicited with a peptide agonist ofPAR2 (SLIGRL‐NH2). Zymography indicated that tryptase stimulated the release of matrix metalloproteinases (MMP) 2 and 9 in the peritoneum of both mouse strains. Studies involving immunomagnetic isolation of neutrophils suggested that neutrophils represent the major cellular source of tryptase‐inducedMMP2 andMMP9. At 24 hours after tryptase injection, there was increased microvascular leakage as indicated by high levels of albumin in peritoneal lavage fluid, and this appeared to be partially abolished by heat‐inactivating tryptase or addition of a protease inhibitor. There was no corresponding increase in levels of histamine or total protein. The extent of tryptase‐induced microvascular leakage or gelatinase release into the peritoneum did not differ betweenPAR2‐deficient and wild‐type mice.Conclusions: Our findings indicate that tryptase is a potent stimulus for neutrophil accumulation,MMPrelease and microvascular leakage. Although these actions required an intact catalytic site, the primary mechanism of tryptase in vivo would appear to involve processes independent ofPAR2.
Ultrasonic standing wave systems have previously been used for the generation of 3D constructs for a range of cell types. In the present study, we cultured cells from the human hepatoma Huh7 cell line in a Bulk Acoustic Wave field and studied their viability, their functions, and their response to the anti-cancer drug, 5 Fluorouracil (5FU). We found that cells grown in the acoustofluidic bioreactor (AFB) expressed no reduction in viability up to 6 h of exposure compared to those cultured in a conventional 2D system. In addition, constructs created in the AFB and subsequently cultured outside of it had improved functionality including higher albumin and urea production than 2D or pellet cultures. The viability of Huh7 cells grown in the ultrasound field to 5FU anti-cancer drug was comparable to that of cells cultured in the 2D system, showing rapid diffusion into the aggregate core. We have shown that AFB formed 3D cell constructs have improved functionality over the conventional 2D monolayer and could be a promising model for anti-cancer drug testing.
31 August 2011 in International Immunopharmacology
Eczema is also known as atopic dermatitis is well-known for the skin disease globally. In Saudi Arabia, exome sequencing studies have not been documented. The purpose of this study was to scrutinize the disease causing mutations in children affected with eczema with exome sequencing in the Saudi population. We recruited randomly three sporadic cases of children diagnosed with eczema and simultaneously, three more cases were adopted for control samples. Exome sequencing was carried out by applying a pipeline that captures all the variants of concern related to the samples by using the Ion torrent. In this study, we have documented 49 variants, among which 37 variants were confirmed through eczema children and remaining 30 variants through control children. However, from the analysis of the 6 samples, we have identified rs10192157 (1646C>T; Thr549Ile), rs2899642 (27C>G; Asn9Lys), chr1:152127950 (1625G>A; Gly542Asp) and chr1:152128041 (1534C>G; Gly512Arg) variants which are rarely linked to the disease eczema. In the rs10192157, we have documented these mutations in all three eczema children and one in the control; the rs2899642 mutation appeared in only a couple of eczema children, whereas the mutation in the chr1:152127950 regions appeared in only one eczema patient. However, the chr1:152128041 mutations appeared in only one case of eczema and also in two control children. Our study revealed four mutations which had not previously been connected with eczema within the database. However, the rs10192157 and rs2899642 mutations were documented with asthma disease. The remaining mutations such as chr1:152127950 and chr1:152128041 have not been reported anywhere else. This study recommends screening these 4 mutations in eczema cases and their relevant controls to confirm the prevalence in the Saudi population. It is recommended that future studies examine the 4 mutations in detail.